Clinical Trial Update: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF [Phase 2]

View source ↗

Summary

A Phase 2 trial (CONVERT-AF) evaluating canakinumab to prevent recurrences of atrial fibrillation after electrical cardioversion was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Atrial Fibrillation | Phase 2 | Status: TERMINATED